お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
391386

癌ワクチンの世界市場:成長、動向、および予測(2019年~2024年)

Cancer Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
癌ワクチンの世界市場:成長、動向、および予測(2019年~2024年)
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の癌ワクチン市場は、2019年から2024年の間に16.7%のCAGRで成長する見通しです。

当レポートは世界の癌ワクチン市場について調査しており、市場機会や動向、成長および阻害要因、技術・治療方法・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 技術別
    • 組換え癌ワクチン
    • 全細胞癌ワクチン
    • ウイルスベクター・DNA癌ワクチン
    • その他(樹状細胞、抗原など)
  • 治療法別
    • 予防ワクチン
    • 治療ワクチン
  • 用途別
    • 前立腺癌
    • 子宮頸癌
    • その他(肝臓癌、皮膚癌など)
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Aduro BioTech, Inc.
    • Astellas Pharma, Inc.
    • AstraZeneca PLC
    • Bristol-Myers Squibb
    • Dendreon
    • GlaxoSmithKline
    • Merck & Co., Inc.
    • OSE Immunotherapeutics
    • Sanofi

第7章 市場機会および将来動向

目次
Product Code: 51683

Certain factors that are driving the Cancer Vaccines market's growth include the increasing number of cancer cases, rising investments and government funding in the development of cancer vaccines, and technological developments in cancer vaccines.

The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Cancer damages the immune system, as cancer cells produce self-antigen. The cancer vaccines play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers. These cancer vaccines target the infectious agents that may cause cancer, through the production of the antibodies. Cancer vaccines are considered to be a new therapy and are not popular, as compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways.

Moreover, healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side effects of the present therapies. Hence, the market for cancer vaccines is expected to grow at a high rate, during the forecast period.

However, in the expanding market for medical therapies, there are stringent regulatory policies in place, to ensure the safety of those therapies. The presence of stringent regulations is hindering the growth of this market.

Key Market Trends

Preventive Vaccines are Expected to a Hold Significant Market Share in the Treatment Method

Preventive vaccines or prophylactic vaccines are the vaccines intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer.

There are two types of cancer prevention vaccines approved by the US Food and Drug Administration (FDA), which include the human papillomavirus vaccine (HPV) and hepatitis B vaccine. According to the National Cancer Institute, the three vaccines approved by the US Food and Drug Administration to prevent human papillomaviruses (HPV) infection are Gardasil, Gardasil 9, and Cervarix. While Gardasil and Gardasil 9 were approved for use among women for the prevention of HPV-caused cervical, vaginal, and anal cancers, Cervarix was approved for the prevention of cervical cancer among women, which is caused by HPV. Hepatitis B vaccine prevents hepatitis B virus (HBV) infection, as prolonged infection with HBV can lead to liver cancer. Moreover, the demand for these vaccines and research in other forms of cancer is expected to increase due to rising incidence of cancer globally.

North America Dominates the Market and is also Expected to do so during the Forecast Period

North America is expected to grow due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. According to the National Cancer Institute, preventive vaccines were approved to treat cancers, by the use of vaccines, namely Human papillomavirus (HPV) vaccines and the Hepatitis B virus (HBV). However, there are many other vaccines that are approved by the FDA, for the prevention of cancer.

In April 2010, the first cancer treatment vaccine, called sipuleucel-T (Provenge), was approved by the FDA. This vaccine was approved to be used on men with metastatic prostate cancer. It was designed to stimulate an immune response to prostatic acid phosphatase (PAP), which is an antigen found in most prostate cancer cells. Moreover, in October 2015, the first oncolytic virus therapy, called talimogene laherparepvec (T-VEC, or Imlygic), was also approved by the FDA. This vaccine is used for the treatment of metastatic melanoma, which cannot be surgically removed.

Competitive Landscape

The global cancer vaccines market is highly consolidated and consists of a few major players. Companies, like Aduro BioTech Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, Dendreon, GlaxoSmithKline, Merck & Co. Inc., OSE Immunotherapeutics, Sanofi, and Welland Medical Ltd, among others, hold substantial shares in the cancer vaccines market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Cancer Cases
    • 4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
    • 4.2.3 Technological Developments in Cancer Vaccines
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
    • 4.3.2 Presence of Alternative Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Technology
    • 5.1.1 Recombinant Cancer Vaccines
    • 5.1.2 Whole-cell Cancer Vaccines
    • 5.1.3 Viral Vector and DNA Cancer Vaccines
    • 5.1.4 Other Technologies (Dendritic Cells, Antigen, etc.)
  • 5.2 Treatment Method
    • 5.2.1 Preventive Vaccine
    • 5.2.2 Therapeutic Vaccine
  • 5.3 Application
    • 5.3.1 Prostate Cancer
    • 5.3.2 Cervical Cancer
    • 5.3.3 Other Applications (Liver, Skin, etc.)
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aduro Biotech, Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 Dendreon Pharmaceuticals LLC
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 GlaxoSmithKline PLC
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 OSE Immunotherapeutics
    • 6.1.10 Sanofi SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.